中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
8期
36,39
,共2页
促肝细胞生长素%婴儿%肝炎综合征
促肝細胞生長素%嬰兒%肝炎綜閤徵
촉간세포생장소%영인%간염종합정
Hepatocyte growth-promoting factor%Infant%Hepatitis syndrome
目的 探讨促肝细胞生长素治疗肝炎综合征的疗效.方法 收集2009年1月至2010年7月住院治疗的肝炎综合征患者80例,随机分成治疗组和对照组各40例,两组均采用抗病毒、能量合剂(肝泰乐、肌苷、门冬氨酸钾镁等)护肝利胆、茵栀黄退黄等治疗措施.治疗组在对照组治疗基础上加用促肝细胞生长素30 μg(2 ml),加入5%葡萄糖注射液100 ml中静脉滴注,每天1次,连续治疗2周.结果 治疗2周后,治疗组天门冬氨酸氨基转移酶(AST)和丙氨酸氨基转移酶(ALT)明显下降,而对照组ALT及AST虽然有所下降,但差异无统计学意义(P＞0.05).对照组有效率95%,对照组有效率60%.结论 促肝细胞生长素治疗婴儿肝炎综合征疗效显著,值得推广.
目的 探討促肝細胞生長素治療肝炎綜閤徵的療效.方法 收集2009年1月至2010年7月住院治療的肝炎綜閤徵患者80例,隨機分成治療組和對照組各40例,兩組均採用抗病毒、能量閤劑(肝泰樂、肌苷、門鼕氨痠鉀鎂等)護肝利膽、茵梔黃退黃等治療措施.治療組在對照組治療基礎上加用促肝細胞生長素30 μg(2 ml),加入5%葡萄糖註射液100 ml中靜脈滴註,每天1次,連續治療2週.結果 治療2週後,治療組天門鼕氨痠氨基轉移酶(AST)和丙氨痠氨基轉移酶(ALT)明顯下降,而對照組ALT及AST雖然有所下降,但差異無統計學意義(P＞0.05).對照組有效率95%,對照組有效率60%.結論 促肝細胞生長素治療嬰兒肝炎綜閤徵療效顯著,值得推廣.
목적 탐토촉간세포생장소치료간염종합정적료효.방법 수집2009년1월지2010년7월주원치료적간염종합정환자80례,수궤분성치료조화대조조각40례,량조균채용항병독、능량합제(간태악、기감、문동안산갑미등)호간리담、인치황퇴황등치료조시.치료조재대조조치료기출상가용촉간세포생장소30 μg(2 ml),가입5%포도당주사액100 ml중정맥적주,매천1차,련속치료2주.결과 치료2주후,치료조천문동안산안기전이매(AST)화병안산안기전이매(ALT)명현하강,이대조조ALT급AST수연유소하강,단차이무통계학의의(P＞0.05).대조조유효솔95%,대조조유효솔60%.결론 촉간세포생장소치료영인간염종합정료효현저,치득추엄.
Objective To explore the clinical efficacy of hepatocyte growth-promoting factor in treatment of infantile hepatitis syndrome.Methods Eighty patients of infantile hepatitis syndrome were collected from January 2009 to July 2010,which were randomly divided into two groups.Forty cases as treatment group and 40 cases as control group were all treated by anti-virus,energy mixture(glucurolactone,inosine,potassium magnesium aspartate,etc),protecting liver and cholagogue and Yinzhihuang treatment.The treatment group from conventional therapy were treated with hepatocyte growth-promoting factor injection(30 μg/2 ml)in 5% glucose injection(100 ml),iv gtt,once a day for two weeks.Results After two weeks,the level of aspartate aminotransferase(AST) and alanine aminotransferase(ALT)in the treatment group was significant decline.Though the level of AST and ALT from control group was on the decline,there was no significant difference(P＞0.05).The effective rate was 95% in the treatment group and 60% in the control group.Conclusions The clinical efficacy of hepatocyte growth-promoting factor in treatment of infantile hepatitis syndrom is significant and the method is worth generalizing and applying.
